Reflex bronchoconstriction is most likely to occur with the following form of inhaled antiasthma medication: A. Metered dose spray of drug in solution B. Dry powder rotacap C. Nebuliser D. Nebuliser with spacer

Reflex bronchoconstriction is most likely to occur
with the following form of inhaled antiasthma medication:
A. Metered dose spray of drug in solution
B. Dry powder rotacap
C. Nebuliser
D. Nebuliser with spacer
by

1 Answer

Answer :

B. Dry powder rotacap
by

Related questions

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

Bronchodilators are useful in cough (a) Only when cough is non-productive (b) Only when cough is associated with thick sticky secretions (c) Only when reflex bronchoconstriction is associated (d) Irrespective of nature of cough or associated features Ans: C 51 The common and dose related side effect of salbutamol is (a) Rise in blood pressure (b) Muscle tremor (c) Hyperglycaemia (d) Central nervous system stimulation

Description : Bronchodilators are useful in cough (a) Only when cough is non-productive (b) Only when cough is associated with thick sticky secretions (c) Only when reflex bronchoconstriction is associated (d) ... Rise in blood pressure (b) Muscle tremor (c) Hyperglycaemia (d) Central nervous system stimulation

Last Answer : Ans: B

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Tricyclic antidepressants can alter the oral absorption of many drugs by: A. Complexing with the other drug in the intestinal lumen B. Altering gut motility C. Altering gut flora D. Damaging gut mucosa

Last Answer : C. Altering gut flora

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Which of the following is true of ‘placebos’: A. Placebo is a dummy medication B. Placebo is the inert material added to the drug for making tablets C. Placebos do not produce any effect D. All patients respond to placebos

Description : Which of the following is true of ‘placebos’: A. Placebo is a dummy medication B. Placebo is the inert material added to the drug for making tablets C. Placebos do not produce any effect D. All patients respond to placebos

Last Answer : A. Placebo is a dummy medication

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Description : A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Last Answer : C. Competitive antagonist

The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Description : The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Last Answer : A. Safety

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

A fixed dose combination preparation meant for internal use must not contain the following class of drug: A. Thiazide diuretic B. Fluoroquinolone antimicrobial C. Corticosteroid D. H2 blocker

Description : A fixed dose combination preparation meant for internal use must not contain the following class of drug: A. Thiazide diuretic B. Fluoroquinolone antimicrobial C. Corticosteroid D. H2 blocker

Last Answer : C. Corticosteroid

A drug which is generally administered in standard doses without the need for dose individualization is: A. Insulin B. Mebendazole C. Prednisolone D. Digoxin

Description : A drug which is generally administered in standard doses without the need for dose individualization is: A. Insulin B. Mebendazole C. Prednisolone D. Digoxin

Last Answer : B. Mebendazole

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Description : A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Last Answer : C. Competitive antagonist

The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Description : The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Last Answer : A. Safety

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearanc

If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Description : If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Last Answer : B. Its clearance value will remain constant

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

6 A patient of chronic bronchial asthma was maintained on oral prednisolone 20 mg/day for 3 months. It was decided to switch him over to inhaled beclomethasone dipropionate 200 μg 4 times a day. What should be done to the oral prednisolone medication after starting inhaled beclomethasone: A. It should be stopped immediately B. Its dose should be tapered from the next day C. It should be given at the same dose for one week and then tapered D. Its dose should be doubled for one week and then tapered (p. 2

Description : 6 A patient of chronic bronchial asthma was maintained on oral prednisolone 20 mg/day for 3 months. It was decided to switch him over to inhaled beclomethasone dipropionate 200 μg 4 times a day. What should ... week and then tapered D. Its dose should be doubled for one week and then tapered (p. 2

Last Answer : C. It should be given at the same dose for one week and then tapered

Drug administered through the following route is most likely to be subjected to first-pass metabolism: A. Oral B. Sublingual C. Subcutaneous D. Rectal

Description : Drug administered through the following route is most likely to be subjected to first-pass metabolism: A. Oral B. Sublingual C. Subcutaneous D. Rectal

Last Answer : A. Oral

Out of two anticholinesterases, drug ‘X’ is a tertiary amine while drug ‘Y’ is a quarternary ammonium compound. Then: A. Drug ‘X’ is likely to be more potent than ‘Y’ B. Drug ‘X’ will be more suitable to be used as a miotic C. Drug ‘Y’ will be completely metabolized in the body D. Drug ‘Y’ will produce CNS effects

Description : Out of two anticholinesterases, drug X' is a tertiary amine while drug Y' is a quarternary ammonium compound. Then: A. Drug X' is likely to be more potent than Y' B. Drug X' will be more ... a miotic C. Drug Y' will be completely metabolized in the body D. Drug Y' will produce CNS effects

Last Answer : B. Drug ‘X’ will be more suitable to be used as a miotic

Drug administered through the following route is most likely to be subjected to first-pass metabolism: A. Oral B. Sublingual C. Subcutaneous D. Rectal

Description : Drug administered through the following route is most likely to be subjected to first-pass metabolism: A. Oral B. Sublingual C. Subcutaneous D. Rectal

Last Answer : A. Oral

Which of the following drugs is administered by intranasal spray/application for systemic action: A. Phenylephrine B. Desmopressin C. Azelastine D. Beclomethasone dipropionate

Description : Which of the following drugs is administered by intranasal spray/application for systemic action: A. Phenylephrine B. Desmopressin C. Azelastine D. Beclomethasone dipropionate

Last Answer : B. Desmopressin

Which of the following drugs is administered by intranasal spray/application for systemic action: A. Phenylephrine B. Desmopressin C. Azelastine D. Beclomethasone dipropionate

Description : Which of the following drugs is administered by intranasal spray/application for systemic action: A. Phenylephrine B. Desmopressin C. Azelastine D. Beclomethasone dipropionate

Last Answer : B. Desmopressin

Bronchodilators are useful in cough: A. Only when cough is nonproductive B. Only when cough is associated with thick sticky secretions C. Only when reflex bronchoconstriction is associated D. Irrespective of nature of cough or associated features

Description : Bronchodilators are useful in cough: A. Only when cough is nonproductive B. Only when cough is associated with thick sticky secretions C. Only when reflex bronchoconstriction is associated D. Irrespective of nature of cough or associated features

Last Answer : C. Only when reflex bronchoconstriction is associated

Fixed dose combination formulations are not necessarily appropriate for: A. Drugs administered in standard doses B. Drugs acting by the same mechanism C. Antitubercular drugs D. Antihypertensive drugs

Description : Fixed dose combination formulations are not necessarily appropriate for: A. Drugs administered in standard doses B. Drugs acting by the same mechanism C. Antitubercular drugs D. Antihypertensive drugs

Last Answer : B. Drugs acting by the same mechanism

Which of the following statements is not true of fixed dose combination formulations: A. They are more convenient B. Contraindication to one of the components does not contraindicate the formulation C. The dose of any one component cannot be independently adjusted D. The time course of action of the different components may not be identical

Description : Which of the following statements is not true of fixed dose combination formulations: A. They are more convenient B. Contraindication to one of the components does not contraindicate the formulation ... adjusted D. The time course of action of the different components may not be identical

Last Answer : B. Contraindication to one of the components does not contraindicate the formulation

The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Description : The dose of the following class of drugs has to be adjusted by repeated measurement of the affected physiological parameter: A. Oral contraceptives B. Antiepileptics C. Antidepressants D. Oral anticoagulants

Last Answer : D. Oral anticoagulants

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

Choose the correct statement(s) about ipratropium bromide: A. It preferentially dilates peripheral bronchioles B. It produces additional bronchodilatation when added to nebulized salbutamol C. As metered dose inhaler it is used for terminating asthma attacks D. Both 'B' and 'C'

Description : Choose the correct statement(s) about ipratropium bromide: A. It preferentially dilates peripheral bronchioles B. It produces additional bronchodilatation when added to nebulized salbutamol C. As metered dose inhaler it is used for terminating asthma attacks D. Both 'B' and 'C'

Last Answer : B. It produces additional bronchodilatation when added to nebulized salbutamol

The antiasthma drug which cannot be administered by inhalation is (a) Theophylline (b) Ipratropium bromide (c) Budesonide (d) Terbutaline

Description : The antiasthma drug which cannot be administered by inhalation is (a) Theophylline (b) Ipratropium bromide (c) Budesonide (d) Terbutaline

Last Answer : Ans: A

Select the antiasthma drug which cannot be administered by inhalation: A. Theophylline B. Ipratropium bromide C. Budesonide D. Terbutaline

Description : Select the antiasthma drug which cannot be administered by inhalation: A. Theophylline B. Ipratropium bromide C. Budesonide D. Terbutaline

Last Answer : A. Theophylline

The following antiasthma drug is not a bronchodilator: A. Ipratropium bromide B. Theophylline C. Formoterol D. Sodium cromoglycate

Description : The following antiasthma drug is not a bronchodilator: A. Ipratropium bromide B. Theophylline C. Formoterol D. Sodium cromoglycate

Last Answer : D. Sodium cromoglycate

Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of 2 hours C. An antihypertensive with a plasma half life of 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Description : Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of ... 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Last Answer : Microsomal enzyme induction has one of the following features: A. Takes about one week to develop B. Results in increased affinity of the enzyme for the substrate C. It is irreversible D. Can be used to treat acute drug poisonings

Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Description : Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Last Answer : A. Continuous use of agonists